Purpose: To perform a planned interim analysis of acute (within 12 months) and late (after 12 months) toxicities and cosmetic outcomes after proton accelerated partial breast irradiation (APBI).
Methods and materials: A total of 100 patients with pTis or pT1-2 N0 (≤3cm) breast cancer status after segmental mastectomy were enrolled in a single-arm phase 2 study from 2010 to 2019. The clinically determined postlumpectomy target volume, including tumor bed surgical clips and operative-cavity soft-tissue changes seen on imaging plus a radial clinical expansion, was irradiated with passively scattered proton APBI (34 Gy in 10 fractions delivered twice daily with a minimum 6-hour interfraction interval). Patients were evaluated at protocol-specific time intervals for recurrence, physician reports of cosmetic outcomes and toxicities, and patient reports of cosmetic outcomes and satisfaction with the treatment or experience.
Results: Median follow-up was 24 months (interquartile range [IQR], 12-43 months). Local control and overall survival were 100% at 12 and 24 months. There were no acute or late toxicities of grade 3 or higher; no patients experienced fat necrosis, fibrosis, infection, or breast shrinkage. Excellent or good cosmesis at 12 months was reported by 91% of patients and 94% of physicians; at the most recent follow-up, these were 94% and 87%, respectively. The most commonly reported late cosmetic effect was telangiectasis (17%). The total patient satisfaction rate for treatment and results at 12 and 24 months was 96% and 100%, respectively. Patients' mean time away from work was 5 days (IQR, 2-5 days), and the median out-of-pocket cost was $700 (IQR, $100-$1600). The mean left-sided heart dose was 2 cGy (range, 0.2-75 cGy), and the mean ipsilateral lung dose was 19 cGy (range, 0.2-164 cGy).
Conclusions: Proton APBI is a maturing treatment option with high local control, favorable intermediate-term cosmesis, high treatment satisfaction, low treatment burden, and exceptional heart and lung sparing.
Copyright © 2020 Elsevier Inc. All rights reserved.
Chang JH, Lee NK, Kim JY, Kim YJ, Moon SH, Kim TH, Kim JY, Kim DY, Cho KH, Shin KH. Chang JH, et al. Radiother Oncol. 2013 Aug;108(2):209-14. doi: 10.1016/j.radonc.2013.06.008. Epub 2013 Jul 25. Radiother Oncol. 2013. PMID: 23891102 Clinical Trial.
Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Fietkau R, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Uter W, Strnad V; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Polgár C, et al. Lancet Oncol. 2017 Feb;18(2):259-268. doi: 10.1016/S1470-2045(17)30011-6. Epub 2017 Jan 14. Lancet Oncol. 2017. PMID: 28094198 Clinical Trial.
Galland-Girodet S, Pashtan I, MacDonald SM, Ancukiewicz M, Hirsch AE, Kachnic LA, Specht M, Gadd M, Smith BL, Powell SN, Recht A, Taghian AG. Galland-Girodet S, et al. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):493-500. doi: 10.1016/j.ijrobp.2014.04.008. Epub 2014 May 29. Int J Radiat Oncol Biol Phys. 2014. PMID: 24880212 Clinical Trial.
Bush DA, Do S, Lum S, Garberoglio C, Mirshahidi H, Patyal B, Grove R, Slater JD. Bush DA, et al. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):501-5. doi: 10.1016/j.ijrobp.2014.05.1308. Epub 2014 Jul 30. Int J Radiat Oncol Biol Phys. 2014. PMID: 25084608 Clinical Trial.
Lehman M, Hickey BE, Francis DP, See AM. Lehman M, et al. Cochrane Database Syst Rev. 2014 Jun 18;(6):CD007077. doi: 10.1002/14651858.CD007077.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Jul 18;7:CD007077. doi: 10.1002/14651858.CD007077.pub3. PMID: 24938937 Updated. Review.
Freedman GM, Li T, Garver E, Shillington K, Shinkle B, Tchou JC, Fayanju OM, Lin L, Taunk NK. Freedman GM, et al. Adv Radiat Oncol. 2023 Aug 6;9(2):101334. doi: 10.1016/j.adro.2023.101334. eCollection 2024 Feb. Adv Radiat Oncol. 2023. PMID: 38405317 Free PMC article.
Wu XY, Chen M, Cao L, Li M, Chen JY. Wu XY, et al. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241234788. doi: 10.1177/15330338241234788. Technol Cancer Res Treat. 2024. PMID: 38389426 Free PMC article. Review.
Ruan H, Okamoto M, Ohno T, Li Y, Zhou Y. Ruan H, et al. Front Oncol. 2023 Aug 16;13:1107703. doi: 10.3389/fonc.2023.1107703. eCollection 2023. Front Oncol. 2023. PMID: 37655110 Free PMC article. Review.
Choi JI, Prabhu K, Hartsell WF, DeWees T, Sinesi C, Vargas C, Benda RK, Cahlon O, Chang AL. Choi JI, et al. Clin Transl Radiat Oncol. 2022 Aug 28;37:71-77. doi: 10.1016/j.ctro.2022.08.013. eCollection 2022 Nov. Clin Transl Radiat Oncol. 2022. PMID: 36093343 Free PMC article.
Fastner G, Reitsamer R, Gaisberger C, Hitzl W, Urbański B, Murawa D, Matuschek C, Budach W, Ciabattoni A, Reiland J, Molnar M, Vidali C, Schumacher C, Sedlmayer F, On Behalf Of The Hiob Trialist Group. Fastner G, et al. Cancers (Basel). 2022 Mar 9;14(6):1396. doi: 10.3390/cancers14061396. Cancers (Basel). 2022. PMID: 35326548 Free PMC article.